B cells meanwhile upregulated CD86(P<0.05) in response to ox-L, but not MHC-II, CD40 or CD80.Taken together, these results suggest a capacity for enhanced T-cell responsesto oxidized tumour lysate if both DCs and B cells are presenting the lysateantigens, as opposed to DCs alone, as is currently the case in the clinic. This evidence concerns the gene CD86 and neoplasm.